Abstract
Purpose:
To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFalpha agent.
Design:
Single interventional case report.
Methods:
A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab (Remicade, Centocor) treatment for Ankylosing spondylitis (AS) as part of the open-label phase of a trial conducted at our tertiary referral center. Cultures grew Staphylococcus aureus.
Results:
Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy. Infliximab therapy was resumed after three weeks.
Conclusions:
Clinical vigilance is warranted when treating patients with anti-TNFalpha agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.
MeSH terms
-
Adult
-
Amoxicillin-Potassium Clavulanate Combination / therapeutic use
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Cefotaxime / therapeutic use
-
Cellulitis / diagnosis
-
Cellulitis / drug therapy
-
Cellulitis / etiology*
-
Drug Therapy, Combination
-
Eye Infections, Bacterial / diagnosis
-
Eye Infections, Bacterial / drug therapy
-
Eye Infections, Bacterial / etiology*
-
Humans
-
Infliximab
-
Male
-
Microbial Sensitivity Tests
-
Orbital Diseases / diagnosis
-
Orbital Diseases / drug therapy
-
Orbital Diseases / etiology*
-
Randomized Controlled Trials as Topic
-
Spondylitis, Ankylosing / drug therapy*
-
Staphylococcal Infections / diagnosis
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / etiology*
-
Staphylococcus aureus / isolation & purification
-
Tumor Necrosis Factor-alpha / immunology
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
Amoxicillin-Potassium Clavulanate Combination
-
Infliximab
-
Cefotaxime